Unibest
← Back to patent-cliff list

CAS 253796-85-9

ethyl (4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)glycinate

Codes: DABI-035

Application context (from source-drug indications)

Venous thromboembolismDabigatran Etexilate MesylateEmbolismDabigatran Etexilate MesylateStrokeDabigatran Etexilate MesylateIschaemic strokeDabigatran Etexilate MesylatePulmonary embolismDabigatran Etexilate MesylateVenous thrombosisDabigatran Etexilate Mesylate

Source drugs (routes using this intermediate)

DrugTierExpiry
Dabigatran Etexilate MesylateTier B — Position early-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Intermediates available on this site

Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.

SupplierProductPrice bandMOQLead timeQualificationsAction
Qualified Partner — East China API WorksDabigatran etexilate mesylate
Pharmaceutical Intermediates
On requestOn requestOn request
—
Unibest Nantong cGMP Siteethyl N-[3-amino-4-(methylamino)benzoyl]-N-pyridin-2-yl-beta-alaninate
Pharmaceutical Intermediates
On requestOn requestOn request
—
Unibest Taizhou GMP-like SiteN-(4-cyanophenyl)-Glycine
Pharmaceutical Intermediates
On requestOn requestOn request
—

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.